2021 American Transplant Congress
Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Pediatric Solid Organ Transplant Recipients; Single Center Experience
*Purpose: The main objective of the study is to compare the efficacy of the different Valganciclovir dosing strategies in pediatric solid organ transplant recipients with…2021 American Transplant Congress
An Unusual Viral Tropism in a Solid Organ Transplant Recipient
*Purpose: Cytomegalovirus (CMV) tissue-invasive disease occurs in higher proportion in CMV-mismatched kidney transplant recipients (KTxR) with no pre-existing immunity and those who are markedly immunologically-impaired.…2020 American Transplant Congress
Cytomegalovirus Infection and Disease in Pediatric Liver Transplantation: Burden of Disease Under a Preemptive Therapy Approach
Transplant Department, Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico
*Purpose: To report the incidence cytomegalovirus (CMV) infection (CMV-I) and disease (CMV-D) in a cohort of pediatric liver transplant recipients under preemptive therapy, identify risk…2020 American Transplant Congress
Cytomegalovirus Preemptive Monitoring Conversion and the Use of a Preemptive Threshold after Solid Organ Transplant
*Purpose: Cytomegalovirus (CMV) in solid organ transplant (SOT) is associated with negative graft and patient outcomes. Prophylactic agents of choice have substantial cytotoxicity, and patients…2020 American Transplant Congress
Pharmacist Management after Preemptive Monitoring Conversion as a Component of a Cytomegalovirus Antiviral Stewardship Program at a Large Transplant Center
*Purpose: Cytomegalovirus (CMV) in solid organ transplant (SOT) is associated with negative graft and patient outcomes. Prophylactic agents of choice have substantial cytotoxicity, and patients…2020 American Transplant Congress
Low Level CMV Detection and Effectiveness of Low Dose Valganciclovir Prophylaxis in Intermediate-Risk Liver Transplant Recipients
*Purpose: The purpose of this study is to assess the efficacy of low dose (450 mg/day) valganciclovir in preventing CMV infection in intermediate-risk liver transplant…2020 American Transplant Congress
Evaluation of Cytomegalovirus Prophylaxis in Low and Intermediate Risk Kidney Transplant Recipients Receiving Lymphocyte-Depleting Induction
Hartford Hospital, Hartford, CT
*Purpose: This study evaluates if choice and duration of Cytomegalovirus (CMV) prophylaxis based on donor (D) and recipient (R) CMV serostatus impacts the incidence of…2020 American Transplant Congress
T Cell Dysfunction as Measured by Impaired Antigen Response is Associated with Infection and Frailty in Kidney Transplant Recipients
David Geffen School of Medicine at UCLA, Los Angeles, CA
*Purpose: Kidney transplant recipients are at risk for infection, especially the growing numbers of older patients. Our previous studies demonstrated that senescent and exhausted T…2020 American Transplant Congress
Lack of Drug-Drug Interaction between Maribavir and Voriconazole
*Purpose: Maribavir is being evaluated in Phase 3 trials for the treatment of cytomegalovirus infections in transplant recipients. These patients often take numerous concomitant medications,…2020 American Transplant Congress
Incidence of Cytomegalovirus Infection in Deceased Donor Kidney Transplantation from Hepatitis-C Antibody Positive Donors to Hepatitis-C Antibody Negative Recipients: A National Registry Analysis
*Purpose: Deceased donor kidney transplantation (KT) from hepatitis C (HCV) infected donors into HCV uninfected recipients (HCV D+/R-) will be the standard of care in…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 33
- Next Page »